News

14
Dec

NEPTUNUS-2 Study: Sjogren’s Syndrome Clinical Trial Approved in 8 Weeks via CATALIS’ FAST TRACK Evaluation Service

NEPTUNUS-2 Study: Sjogren’s Syndrome Clinical Trial Approved in 8 Weeks via CATALIS’ FAST TRACK Evaluation Service   As mentioned in our December 2022 newsletter, CATALIS is proud to announce that its FAST TRACK Evaluation Service continues to allow industry-financed studies to be authorized in record time. In NEPTUNUS-2, a phase III study, Novartis and Dr. Isabelle Fortin are testing the

Read more

14
Dec

ONWARDS Study: Authorization in 9 Weeks for Symptomatic Osteoarthritis of the Knee Study via CATALIS’ FAST TRACK Evaluation Service

ONWARDS Study: Authorization in 9 Weeks for Symptomatic Osteoarthritis of the Knee Study via CATALIS’ FAST TRACK Evaluation Service   In addition to the 3 rare disease studies, a 4th Novartis study on symptomatic osteoarthritis of the knee was authorized by the Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS) in record time via the CATALIS FAST TRACK

Read more

14
Dec

The Personalized Clinical Trial Support Service Assists Patients with Various Diseases, Including Rare Ones

The Personalized Clinical Trial Support Service Assists Patients with Various Diseases, Including Rare Ones   CATALIS, under the banner Clinical Trials Quebec, is continuing the pilot implementation of its Personalized Clinical Trial Service. This province-wide, bilingual resource is free of charge; it is designed to help Quebec patients and their caregivers, regardless of their age or medical condition. This service

Read more

13
Dec

CATALIS’ Management Being Supported by Two New Advisory Committees

CATALIS’ Management Being Supported by Two New Advisory Committees   Until recently, CATALIS’ management has been guided by three main advisory committees: a patient advisory committee made up of fifteen patient and patient-partner associations, a scientific and innovation advisory committee made up of expert clinical researchers, and an operations advisory committee made up of senior representatives from health institutions, pharmaceutical

Read more

14
Sep

Sanofi Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service

Sanofi Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service   Following Novartis, Boehringer, and Roche, Sanofi is now CATALIS’ fourth pharmaceutical partner to pilot its FAST TRACK Evaluation Service. Sanofi’s Phase I-ll study, which uses human subjects for the first time and is designed to assess the safety and the pharmacokinetic, pharmacodynamic, and antitumor activity

Read more

14
Sep

Roche Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service

Roche Pharmaceutical Company’s First Clinical Trial Approved Through CATALIS Quebec’s FAST TRACK Evaluation Service   Thanks to CATALIS’ FAST TRACK evaluation service, Roche’s ProHer multi-centre study, which explores a new treatment method for patients with breast cancer, was approved in 10 weeks by the CHU de Québec-Université Laval. More specifically, this study seeks to discover patients’ preference for at-home administration

Read more

20
Jun

CATALIS Quebec Partners With N2 Canada for Provincial Contract Access to the CITI-Canada Training Platform

CATALIS Quebec Partners With N2 Canada for Provincial Contract Access to the CITI-Canada Training Platform   CATALIS Quebec is very proud to partner with N2 Canada to provide its Network member healthcare institutions access to a shared training platform designed to ensure the conduct of high-quality research: the CITI-Canada training platform. Through this partnership, CATALIS Quebec officially becomes the new

Read more

19
May

Two New Projects Successfully Authorized Within Seven Weeks Thanks to CATALIS QUEBEC’S FAST TRACK Evaluation Service

Two New Projects Successfully Authorized Within Seven Weeks Thanks to CATALIS QUEBEC’S FAST TRACK Evaluation Service   While the first-ever FAST TRACK evaluation service pilot project was successfully completed last December, CATALIS is proud to announce that two more clinical trials have now been approved in record time. The second FAST TRACK evaluation service coordinated a Phase I oncology study

Read more

19
May

Launch of New Shared Clinical Research Tools

Launch of New Shared Clinical Research Tools CATALIS and its network of public and private partners have facilitated the implementation of new shared tools designed to optimize the launching and conducting of clinical trials in Quebec; more specifically, CATALIS has coordinated the revision of documents serving to optimize the contract negotiation process with private industry and a memo which serves to

Read more

11
Apr

Danika Laberge Has Been Appointed President and Chief Executive Officer of CATALIS Quebec

Danika Laberge Has Been Appointed President and Chief Executive Officer of CATALIS Quebec   CATALIS Quebec’s Board of Directors is pleased to announce the appointment of Danika Laberge as the organization’s President and Chief Executive Officer (CEO). “It is with tremendous enthusiasm and confidence in her abilities that the Board of Directors has appointed Ms. Laberge to the position of

Read more